Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-BRENTUXIMAB-VEDOTIN DRUG-DOXORUBICIN DRUG-VINBLASTINE DRUG-DACARBAZINE |
|---|
| ID | REG-A-AVD |
|---|---|
| Type | Protocole thérapeutique |
| État | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
ECHELON-1 trial (Connors 2018, follow-up 2022): superior OS for advanced cHL vs ABVD (HR ~0.59 for OS at 6 years). Bleomycin replaced by brentuximab → eliminates BPT risk. G-CSF mandatory (vs ABVD where G-CSF is not routinely required, but is not universally contraindicated). Preferred 1L for advanced Hodgkin per NCCN where brentuximab accessible.
These citations cover only the statements and scopes shown. They do not establish clinical approval of this record.
BV-AVD requires primary G-CSF prophylaxis and neuropathy monitoring for both brentuximab vedotin and vinblastine. Both use days 1 and 15 of a 28-day cycle, not R-CHOP monitoring.
Regimen-specific monitoring only; not whole-record efficacy, eligibility, dosing or pediatric clinical approval.
eviQ 4449 Treatment schedule, Clinical information and Pre-treatment assessment.
IND-CHL-1L-A-AVD - IND-CHL-1L-A-AVDMON-A-AVD-REGIMEN - MON-A-AVD-REGIMEN